Transcript of Q1 FY27 earnings conference call held on Wednesday, August 05, 2026

Ref: MHL/Sec&Legal/2026-27/37 August 10, 2026 BSE Limited National Stock Exchange of India Limited Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Earnings call transcript for Q1 FY27 Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the transcript of Q1 FY27 earnings conference call held on Wednesday, August 05, 2026. The transcript is also available on the Company’s website i.e. www.metropolisindia.com You are requested to take the above information on record. Thanking you, Yours faithfully, For Metropolis Healthcare Limited Kamlesh C Kulkarni Head – Legal & Secretarial Encl: a/a “Metropolis Healthcare Limited Q1 FY'27 Earnings Conference Call” August 05, 2026 E&OE - This transcript is edited for factual errors. In case of discrepancy, the audio recording uploaded on the stock exchanges on August 05, 2026 will prevail. MANAGEMENT: MS. AMEERA SHAH – CHAIRPERSON & WHOLE-TIME DIRECTOR, METROPOLIS HEALTHCARE LIMITED MR. SURENDRAN CHEMMENKOTIL – MANAGING DIRECTOR, METROPOLIS HEALTHCARE LIMITED MR. SAMEER PATEL – CHIEF FINANCIAL OFFICER, METROPOLIS HEALTHCARE LIMITED MR. MOHAN MENON – CHIEF MARKETING OFFICER, METROPOLIS HEALTHCARE LIMITED MODERATOR: MR. ABIN BENNY – JM FINANCIAL INSTITUTIONAL SECURITIES LIMITED Page 1 of 20 Metropolis Healthcare Limited August 05, 2026 Moderator: Ladies and gentlemen, good day, and welcome to the Q1 FY 2027 Earnings Conference Call of Metropolis Healthcare Limited, hosted by JM Financial Institutional Securities. This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions and expectations of the company as on the date of this call. These statements do not guarantee the future performance of the company and may involve risks and uncertainties which are difficult to predict. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing “*” then “0” on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Abin Benny from JM Financial Institutional Securities. Thank you, and over to you, sir. Abin Benny: Thank you, Alaric. Good morning, and warm welcome to all participants on the Metropolis Healthcare Q1 FY 2027 Earnings Call hosted by JM Financial. Today on this call, we have with us the Management, Ms. Ameera Shah – Promoter and Chairperson, Mr. Surendran Chemmenkotil – Managing Director, Mr. Sameer Patel – Chief Financial Officer, and Mr. Mohan Menon – the Chief Marketing Officer. I will now hand over the call to Ms. Ameera Shah for her opening remarks. Thank you, and over to you, ma'am. Ameera Shah: Hi. Good morning, everyone, and thank you for joining us today for the Q1 FY 2027 Earnings Conference Call at Metropolis Healthcare. I am joined by Surendran – MD, Sameer Patel – CFO, Mohan Menon – CMO, and the rest of our leadership team, along with SGA, our Investor Relations Partner. We have uploaded the Investor Presentations on the Exchanges and website, and I hope you have had an opportunity to go through the same. To give you a brief perspective on the broader landscape before I move to company-specific updates, the Indian diagnostics industry is entering a phase of sustained structural growth supported by three reinforcing shifts: 1. Patients, clinicians, and institutions are moving towards organized quality-led diagnostic providers as expectations around accuracy, consistency, advanced testing capabilities and service standards continue to rise. This is accelerating the shift away from non-standardized, unorganized diagnostics and creating an opportunity for trusted branded players with scale and quality. Page 2 of 20 Metropolis Healthcare Limited August 05, 2026 2. India's healthcare ecosystem is expanding beyond metropolitan markets. New hospital capacity, rising OPD and IPD volumes, greater availability of specialists, and improving access across Tier-2 and Tier-3 cities are bringing more patients into the formal healthcare system. Hospitals and institutional partners are also outsourcing a larger share of specialized and high-end testing to providers with strong quality systems, comprehensive test menus, scientific depth and nationwide reach. 3. Treatment pathways are becoming more advanced. The pharma industry's growing focus on targeted therapies, biologics and biosimilars across oncology, neurology and autoimmune disorders is increasing the need for precise diagnosis, patient stratification, biomarker-led treatment selection and ongoing monitoring. This is expanding the role of molecular, genomic and immunological testing across the patient journey. Together, these shifts are broadening the addressable market for diagnostics and creating a strong structural opportunity in Specialty Testing. However this opportunity will not accrue evenly across the industry. Specialty Diagnostics is an attractive segment, but it is not an automatic ride to win. Success cannot be built simply by adding new tests or investing in advanced equipment. It requires years of investment in scientific expertise, quality systems, clinical credibility, specialist relationships, and a broad high-end test portfolio. These capabilities create meaningful entry barriers and differentiate providers that can participate sustainably in this market. Metropolis has built these capabilities over several decades. Our Specialty portfolio comprises more than 2,200 tests across gastroenterology, nephrology, neurology, oncology, and chronic disease categories, including allergy and autoimmunity. This breadth allows us to support specialist-led pathways across diagnosis, treatment selection and ongoing monitoring. We have also added 36 new tests during the quarter, following 347 additions in FY 2026, including the integration of the core test menu, further strengthening our capabilities across high- growth, high-value Specialty categories. Our scientific differentiation is supported by a 99% EQAS score, which is an External Quality Assurance Score, 99.99% report accuracy and a lab network in which every lab is either accredited or benchmarked to recognize quality standards. Around 30,000 specialist doctors across the country prescribe tests through Metropolis and every leading hospital individual and chain in the country, reflecting the depth of clinician trust built over many years through scientific programs, educational initiatives, sustained engagement and a deeply scientifically operational culture at Metropolis, which manages the trust earned over years. On the tech and digital transformation front, technology remains a strategic pillar of our long- term growth. We are executing a company-wide automation and digital transformation program spanning labs, customer engagement, vendor consolidation, commercial operations, finance, procurement and support functions. Across these initiatives, we are strengthening data Page 3 of 20 Metropolis Healthcare Limited August 05, 2026 governance and ensuring DPDP-compliant handling of patient data with a clear focus on privacy, security, and responsible use of information. Within labs, automation and in-platform standardization are improving quality, throughput and turnaround times, particularly in oncology and Specialty Diagnostics. Beyond Laboratories, AI and automation are improving workflow efficiency, strengthening decision-making, enhancing customer engagement, improving inventory management, and simplifying back office operations. Taken together, these initiatives are creating meaningful productivity gains and building a more scalable, data-led, and efficient operating model across the organization. This growth continues to be anchored in quality, with strong external qua [Showing first 8,000 characters — download PDF for full document]